346 related articles for article (PubMed ID: 15074165)
1. Economic and policy implications of reimportation: a Canadian perspective.
Ward C
Manag Care; 2004 Mar; 13(3 Suppl):17-20. PubMed ID: 15074165
[No Abstract] [Full Text] [Related]
2. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
3. Reimportation of pharmaceuticals: economic and policy implications. Proceedings from an internet presentation, October 29-31, 2003.
Manag Care; 2004 Mar; 13(3 Suppl):1-44. PubMed ID: 15137376
[No Abstract] [Full Text] [Related]
4. Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Ghosh S
Fla J Int Law; 2002; 14(2):217-60. PubMed ID: 16526138
[No Abstract] [Full Text] [Related]
5. More drugs, less protection.
Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
[No Abstract] [Full Text] [Related]
6. Seizures of Canadian drugs rise as Congress, Customs spar.
Carreyrou J
Wall St J (East Ed); 2006 Jul; ():B1, B8. PubMed ID: 16909501
[No Abstract] [Full Text] [Related]
7. Canadian drug reimportation debate goes on.
Johnson N
Drug Discov Today; 2005 May; 10(10):678-9. PubMed ID: 15896676
[No Abstract] [Full Text] [Related]
8. TRIPS, pharmaceuticals, developing countries, and the Doha "solution".
Sykes AO
Chic J Int Law; 2002; 3(1):47-68. PubMed ID: 15709299
[No Abstract] [Full Text] [Related]
9. The effect of drug reimportation on managed care pharmacy.
Penna P
Manag Care Interface; 2003 Jul; 16(7):41-2. PubMed ID: 12908216
[No Abstract] [Full Text] [Related]
10. Public policy implications of cross-border Internet pharmacies.
Cohen JC
Manag Care; 2004 Mar; 13(3 Suppl):14-6. PubMed ID: 15074164
[No Abstract] [Full Text] [Related]
11. Pharmaceutical expenditure compared across countries.
van Mosseveld C
Can J Clin Pharmacol; 2005; 12(3):e269-75. PubMed ID: 16373959
[TBL] [Abstract][Full Text] [Related]
12. Increased direct-to-consumer advertising driving pharmaceutical costs, trends.
Fine A
Exec Solut Healthc Manag; 1999 Jan; 2(1):2-3. PubMed ID: 10345986
[No Abstract] [Full Text] [Related]
13. Illegal importation of pharmaceuticals: implications for community pharmacy and public health.
Fuller C
Manag Care; 2004 Mar; 13(3 Suppl):34-5. PubMed ID: 15074169
[No Abstract] [Full Text] [Related]
14. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
15. FDA chief attacks Canada's drug price controls.
Webster P
Lancet; 2003 Nov; 362(9398):1816. PubMed ID: 14661624
[No Abstract] [Full Text] [Related]
16. Remarks delivered at the Food and Drug Law Institute's 48th Annual Conference.
Enzi MB
Food Drug Law J; 2005; 60(2):103-6. PubMed ID: 16097090
[No Abstract] [Full Text] [Related]
17. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
18. Access to essential drugs.
Dev World Bioeth; 2001 Nov; 1(2):89-92. PubMed ID: 12870517
[No Abstract] [Full Text] [Related]
19. Anti-Glaxo campaign heats up in United States.
Moynihan R
BMJ; 2003 Feb; 326(7386):413. PubMed ID: 12595358
[No Abstract] [Full Text] [Related]
20. Link cost to clinical outcome.
Norris J
BMJ; 2007 May; 334(7601):968. PubMed ID: 17493992
[No Abstract] [Full Text] [Related]
[Next] [New Search]
